ShangPharma has planned to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, ShangPharma and Qidong Biopharma Industrial Zone will invest $60 million to build a comprehensive and multifunctional preclinical research facility as well as a state-of-the-art biologics manufacturing facility.
The preclinical facility will be operated by ShangPharma’s CRO division, ChemPartner and the Biologics manufacturing facility will be operated by ShangPharma's CMO division, China Gateway Biologics. During the construction phase of the manufacturing facility, the company’s existing biologics CMC facility will continue to operate out of its Shanghai site.
The new China Gateway Biologics manufacturing facility will provide commercial scale operations for biopharmaceuticals. It will be comprised of one 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing. Those capabilities will be complemented with fill and finish capabilities of the appropriate scale.
The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.